MA50786A - Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques - Google Patents
Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriquesInfo
- Publication number
- MA50786A MA50786A MA050786A MA50786A MA50786A MA 50786 A MA50786 A MA 50786A MA 050786 A MA050786 A MA 050786A MA 50786 A MA50786 A MA 50786A MA 50786 A MA50786 A MA 50786A
- Authority
- MA
- Morocco
- Prior art keywords
- neurological
- treatment
- combination product
- psychiatric disorders
- psychiatric
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000013066 combination product Substances 0.000 title 1
- 229940127555 combination product Drugs 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382718 | 2017-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50786A true MA50786A (fr) | 2022-04-27 |
Family
ID=60382132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050786A MA50786A (fr) | 2017-10-26 | 2018-10-26 | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11723894B2 (fr) |
| EP (1) | EP3713568A1 (fr) |
| MA (1) | MA50786A (fr) |
| WO (1) | WO2019081764A1 (fr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2019081764A1 (fr) | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| PE20220015A1 (es) * | 2019-02-22 | 2022-01-11 | Gh Res Ireland Limited | 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresion |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| AU2020319012A1 (en) * | 2019-07-23 | 2022-02-24 | Caamtech, Inc. | Compositions containing toad secretion compounds |
| CN114599355A (zh) * | 2019-08-13 | 2022-06-07 | 马里兰大学巴尔的摩分校 | 治疗心理和脑部疾病的方法 |
| MX2022005399A (es) * | 2019-11-07 | 2022-07-05 | Small Pharma Ltd | Compuestos. |
| MX2022007994A (es) | 2019-12-26 | 2022-09-23 | Gilgamesh Pharmaceuticals Inc | Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos. |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| CA3172046A1 (fr) | 2020-02-18 | 2021-08-26 | Gilgamesh Pharmaceuticals, Inc. | Tryptamines specifiques destinees a etre utilisees dans le traitement de troubles de l'humeur |
| EP3868364A1 (fr) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aérosol comrpenant 5-methoxy-n,n-dimethyltryptamine |
| AU2021227523B2 (en) * | 2020-02-28 | 2024-05-30 | Universitätsspital Basel | Controlling effects after 5HT2A agonists administration |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| PL3902541T3 (pl) * | 2020-06-02 | 2022-11-14 | Small Pharma Ltd | Kompozycje terapeutyczne zawierające deuterowane lub częściowo deuterowane związki n,n-dimetyltryptaminy |
| EP4149460A1 (fr) * | 2020-06-02 | 2023-03-22 | Small Pharma Ltd | Formes galéniques solides thérapeutiques |
| US12042564B2 (en) * | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (fr) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Compositions thérapeutiques comprenant des composés de n,n-dimethyltryptamine deutérés ou partiellement deutérés |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| AU2021289147A1 (en) | 2020-06-12 | 2023-02-02 | Beckley Psytech Limited | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022047580A1 (fr) * | 2020-09-01 | 2022-03-10 | Magicmed Industries Inc. | Dérivés de psilocybine hydroxylés et leurs procédés d'utilisation |
| MX2023002557A (es) | 2020-09-01 | 2023-05-29 | Enveric Biosciences Canada Inc | Derivados de psilocibina halogenada y metodos de uso. |
| CN116761599A (zh) * | 2020-12-01 | 2023-09-15 | 斯玛尔药物有限公司 | 氘代或部分氘代的n,n-二甲基色胺化合物 |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| EP4255421A1 (fr) * | 2020-12-01 | 2023-10-11 | Small Pharma Ltd | Formulations inhalables |
| WO2022117359A1 (fr) * | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés |
| US20240025850A1 (en) * | 2020-12-09 | 2024-01-25 | Caamtech, Inc. | Dialkyl tryptamines and their therapeutic uses |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| EP4313030A1 (fr) * | 2021-04-01 | 2024-02-07 | Terran Biosciences, Inc. | Méthodes et compositions se rapportant à une thérapie psychédélique et à des modulateurs de récepteurs sérotoninergiques |
| KR20240000516A (ko) | 2021-04-26 | 2024-01-02 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 조성물 및 방법 |
| CA3216939A1 (fr) * | 2021-05-03 | 2022-11-10 | Robert Barrow | Procede de titrage de doses d'agents psychedeliques |
| WO2022235531A1 (fr) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Troubles du mouvement |
| WO2022251169A1 (fr) * | 2021-05-24 | 2022-12-01 | Canna-Chemistries Llc | Sels cristallins de psilocine |
| CN117642383A (zh) * | 2021-05-24 | 2024-03-01 | 卡纳-化学有限责任公司 | 二甲-4-羟色胺的结晶盐 |
| KR20240019152A (ko) | 2021-06-09 | 2024-02-14 | 아타이 테라퓨틱스, 인크. | 신규 전구약물 및 디메틸트립타민의 접합체 |
| TW202317545A (zh) | 2021-07-07 | 2023-05-01 | 美商泰仁生物科學公司 | N,n-二甲基色胺及相關致幻劑及其用途 |
| IL311211A (en) * | 2021-09-03 | 2024-05-01 | Alexander Shulgin Res Institute Inc | Asymmetric allyl tryptamines |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (fr) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Spray nasal à base de diméthyltriptamine pour le traitement personnalisé des troubles neurologiques et psychiatriques |
| EP4429672A1 (fr) | 2021-11-12 | 2024-09-18 | Terran Biosciences Inc. | Psilocybine et o-acétylpsilocine, leurs sels et formes à l'état solide |
| WO2023111544A2 (fr) * | 2021-12-13 | 2023-06-22 | Beckley Psytech Limited | Sel de benzoate de 5-méthoxy-n,n-diméthyltryptamine |
| US12012381B2 (en) | 2021-12-30 | 2024-06-18 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| SE2250051A1 (en) | 2022-01-20 | 2023-07-21 | Amidea Sweden Ab | New pharmaceutical composition and uses thereof |
| WO2023168022A1 (fr) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-cristaux ou sels comprenant de la psilocybine |
| WO2023186830A1 (fr) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-méthoxy-n, n-diméthyltryptamine pour le traitement du ralentissement psychomoteur |
| WO2023186832A1 (fr) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-méthoxy-n,n-diméthyltryptamine pour le traitement du retrait ou du détachement social/émotionnel |
| US20240000795A1 (en) * | 2022-06-30 | 2024-01-04 | Terran Biosciences Inc. | Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US20240116896A1 (en) * | 2022-09-06 | 2024-04-11 | ATAI Life Sciences AG | Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors |
| WO2024097868A1 (fr) * | 2022-11-02 | 2024-05-10 | Caamtech, Inc. | Relations structure-activité pour psilocybine, baéocystine, aerugincine et analogues associés pour produire des effets pharmacologiques |
| CN115813917A (zh) * | 2022-11-02 | 2023-03-21 | 张樟进 | 一种具有快速改善认知功能的化合物及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| MXPA05000294A (es) | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| WO2008116024A2 (fr) | 2007-03-19 | 2008-09-25 | Acadia Pharmaceuticals Inc. | Combinaisons d'agonistes ou antagonistes inverses de 5-ht2a avec antipsychotiques |
| US8986677B2 (en) | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| TW201444552A (zh) * | 2013-03-15 | 2014-12-01 | Chien-Hung Chen | 一種包含ａｍｐｋ激活劑及血清素活性製劑之醫藥組合物及其用途 |
| NL2018190B1 (en) | 2017-01-18 | 2018-07-26 | Procare Beheer B V | Psilocybin or psilocin in combination with cannabinoid |
| WO2019081764A1 (fr) | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| US11045454B2 (en) | 2018-12-06 | 2021-06-29 | Palo Alto Investors LP | Methods of treating food allergy conditions |
| CN114599355A (zh) | 2019-08-13 | 2022-06-07 | 马里兰大学巴尔的摩分校 | 治疗心理和脑部疾病的方法 |
-
2018
- 2018-10-26 WO PCT/EP2018/079503 patent/WO2019081764A1/fr unknown
- 2018-10-26 MA MA050786A patent/MA50786A/fr unknown
- 2018-10-26 US US16/958,226 patent/US11723894B2/en active Active
- 2018-10-26 EP EP18796407.7A patent/EP3713568A1/fr active Pending
-
2023
- 2023-06-21 US US18/339,172 patent/US20230330063A1/en active Pending
- 2023-06-21 US US18/339,174 patent/US20240165079A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11723894B2 (en) | 2023-08-15 |
| EP3713568A1 (fr) | 2020-09-30 |
| US20240165079A1 (en) | 2024-05-23 |
| WO2019081764A1 (fr) | 2019-05-02 |
| US20200397752A1 (en) | 2020-12-24 |
| US20230330063A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50786A (fr) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA46052A (fr) | Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques | |
| MA45050A (fr) | Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie | |
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA47608A (fr) | Anticorps humanisé pour le traitement ou la prévention de troubles cognitifs, son procédé de production et agent pour le traitement ou la prévention de troubles cognitifs l'utilisant | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| SG11202011296VA (en) | Compositions and methods for the treatment of parkinson's disease | |
| MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| MA50441A (fr) | Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) | |
| MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| IL282562A (en) | Composition and use for the treatment of parkinson's disease and related disorders | |
| IL280315A (en) | Methods for treating and preventing Alzheimer's disease | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA54792A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| IL279634A (en) | Preparations and methods for the treatment and prevention of neurological disorders |